Clinical Trial Search

Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…

Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects

Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…

Primary: Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT) — 4; 0 Participants

Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262

Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. — 27.9; 13.1 percentage of participants — p=0.003

Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001

Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes

Primary: Proportion of Eyes With Macular Hole Closure of Inner Retinal Layers Without Rescue Vitrectomy — 10 Eyes

Primary: Visual Acuity — 52 Units on a scale

Primary: Proportion of Subjects With Total PVD at the First Day 14 Post-injection Visit (Vitreous Detachment to the Equator) as Determined by Masked Central Reading Center (CRC)…

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Traction (VMT/VMA) at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain…

Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale

Primary: Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA) — 14; 15; 6 Participants

Primary: Change in Central Retinal Thickness (CRT) — 384.62; 374; 349.15; 357.62 micrometer

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…

Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL

Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes

Primary: Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect — 13.8; 18.2; 31.3; 10 percentage of participants…

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye — 8.3; 5.1 Letters — p=<0.001

Primary: Binocular Best Corrected Distance Visual Acuity — -0.05 logMAR

Primary: Time to Worsening of DME Disease Activity in the Study Eye. — 82.1; 96.1; 19.1 Weeks

Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants

Primary: Subject Reported Overall Vision Quality Using (CLUE)TM Questionnaire — 41.0; 39.0 units on a scale

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 6.8; 8.5; 8.8…

Primary: Vitreal VEGF Levels. — 735.48; 626.09; 141.11; 235.81 pg/ml